Navigation Links
Trubion Pharmaceuticals Provides Announcement Dates for Third-Quarter and Nine Months Earnings Conference Call
Date:11/3/2008

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the third quarter and nine months ended Sept. 30, 2008, after the close of market on Nov. 10, 2008. The company's earnings conference call will take place Nov. 10, 2008, at 2 p.m. PST (5 p.m. EST).

Both live events will be available for viewing on Trubion's website at http://investors.trubion.com/events.cfm.

Third-Quarter and Nine Months Earnings Conference Call: 2 p.m. PST/5 p.m. EST, Nov. 10, 2008

Trubion will host a conference call and webcast to discuss its third-quarter and nine months 2008 financial results. The call will be held Nov. 10 at 2 p.m. PST (5 p.m. EST). The live event will be available on Trubion's website at http://investors.trubion.com/events.cfm, or by calling (877) 440-5804 or (719) 325-4881. A replay of the discussion will be available beginning the evening of Nov. 10 on Trubion's website or by calling (888) 203-1112 or (719) 457-0820, and entering 8489656. The telephone replay will be available through Nov. 17, 2008.

About Trubion

Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com.

TRBN-G

Contact:

Jim DeNike

Senior Director, Corporate Communications

Trubion Pharmaceuticals Inc.

(206) 838-0500

jdenike@trubion.com

http://www.trubion.com

Waggener Edstrom Worldwide Healthcare

Colleen Beauregard

Senior Vice President

(617) 576-5790

colleenb@waggeneredstrom.com


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
2. Trubion Pharmaceuticals Provides Announcement Dates for Second Quarter and First Six Months Earnings Conference Call
3. Trubion Pharmaceuticals Announces Dates for Fourth-Quarter and Year-End 2007 Earnings Conference Call
4. Trubion Announces Presentations at Upcoming Investor Conferences
5. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
6. Pacira Pharmaceuticals Leverages TalentManager(R) from Salary.Com(TM) to Integrate Compensation and Performance Management Processes
7. Genesis Pharmaceuticals Files Counter Claims
8. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
10. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
11. ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Kasmer, a legally blind and certified personal trainer is helping to develop a weight loss ... plans to fix the two major problems leading the fitness industry today:, ... , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a method ... —Johnson is one of the first doctors to perform the treatment. Orthobiologics are ...
(Date:6/24/2016)... ... 2016 , ... Those who have experienced traumatic events may suffer from a ... such as drug or alcohol abuse, as a coping mechanism. To avoid this pain ... following a traumatic event. , Trauma sufferers tend to feel a range of emotions, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Global law firm ... 2016 Legal Elite. The attorneys chosen by their peers for this recognition are considered ... Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Bay Area ... Network,s Dean Center for Tick Borne Illness ... and Rehabilitation, MIT Hacking Medicine, University of California, ... today announced the five finalists of Lyme ... disease.  More than 100 scientists, clinicians, researchers, entrepreneurs, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
Breaking Medicine Technology: